Ballentine Partners LLC Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ballentine Partners LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 917 shares of the biopharmaceutical company’s stock after selling 145 shares during the quarter. Ballentine Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $653,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of REGN. AE Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 19.4% during the 2nd quarter. AE Wealth Management LLC now owns 547 shares of the biopharmaceutical company’s stock worth $575,000 after buying an additional 89 shares during the period. Sei Investments Co. increased its position in shares of Regeneron Pharmaceuticals by 2.2% during the second quarter. Sei Investments Co. now owns 24,944 shares of the biopharmaceutical company’s stock worth $26,214,000 after acquiring an additional 537 shares during the last quarter. Gabelli Funds LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.8% in the second quarter. Gabelli Funds LLC now owns 1,893 shares of the biopharmaceutical company’s stock worth $1,990,000 after acquiring an additional 34 shares in the last quarter. Public Sector Pension Investment Board boosted its holdings in Regeneron Pharmaceuticals by 77.7% in the second quarter. Public Sector Pension Investment Board now owns 3,841 shares of the biopharmaceutical company’s stock valued at $4,037,000 after purchasing an additional 1,679 shares during the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its stake in Regeneron Pharmaceuticals by 61.1% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 20,674 shares of the biopharmaceutical company’s stock valued at $21,729,000 after purchasing an additional 7,840 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Citigroup cut their target price on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 14th. Barclays reduced their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Finally, Evercore ISI lowered their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Stock Down 1.1 %

Shares of Regeneron Pharmaceuticals stock opened at $680.03 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The business’s fifty day moving average price is $733.06 and its two-hundred day moving average price is $943.95. The company has a market capitalization of $74.73 billion, a P/E ratio of 16.83, a PEG ratio of 1.61 and a beta of 0.10.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.